## (19) World Intellectual Property **Organization**

International Bureau



## 

(43) International Publication Date 28 October 2004 (28.10.2004)

PCT

(10) International Publication Number WO 2004/091654 A1

(51) International Patent Classification<sup>7</sup>: 38/00, 45/00, A61P 37/06

A61K 39/395,

(21) International Application Number:

PCT/EP2004/003982

(22) International Filing Date:

15 April 2004 (15.04.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

0315090.1

16 April 2003 (16.04.2003) GB

0308853.1

GB 27 June 2003 (27.06.2003)

- (71) Applicant (for all designated States except AT, US): NO-VARTIS AG [CH/CH]; Lichstrasse 35, CH-4056 Basel (CH).
- (71) Applicant (for AT only): NOVARTIS PHARMA GMBH [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): FORSTNER, [AT/CH]; Bahnhofstrasse 56, CH-4125 Riehen (CH). KLUMPP, Martin [DE/DE]; Leuselhardtweg 20, 79540 Lörrach (DE). LEDER, Lukas [CH/CH]; Schlettstadterstr. 30, CH-4055 Basel (CH). NÜSSLEIN-HILDESHEIM, Barbara [DE/DE]; Markgrafenstrasse 15, 79591 Eimeldingen (DE). RAULF, Friedrich [DE/DE]; Merianstrasse 29, 79104 Freiburg

(DE). WECKBECKER, Gisbert [DE/CH]; Löliring 31, CH-4105 Biel-Benken (CH).

- (74) Agent: GRUBB, Philip; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

## Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: VAV INHIBITION IN GRAFT REJECTION

(57) Abstract: The present invention provides a method for preventing or treating acute or chronic graft rejection in a recipient of cell, tissue or organ allo- or xenotransplant, inflammatory or autoimmune diseases or malignant proliferative disease, comprising the use of an inhibitor of Vav. Further provided are Vav inhibitors, uses, pharmaceutical compositions and therapeutic combinations comprising Vav inhibitors, and screening methods therefor.

